Global Competition Review reported on the Federal Trade Commission’s clearance of S&C client Amgen’s pending $27.8 billion acquisition of Horizon Therapeutics after the parties entered into a settlement involving Horizon’s rare disease treatments. The S&C team representing Amgen included Michael Rosenthal, Renata Hesse, Samantha Hynes, Marielena Doeding and Kolja Ortmann.
For further information, please read “FTC Settles Amgen/Horizon Challenge.”